Table 2 Susceptibility of NS5A RAS to NS5A inhibitors.

From: Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Cell line (OR6c/1B-4)

Daclatasvir

Ledipasvir

Velpatasvir

Elbasvir

Pibrentasvir

EC50 (pM)

Fold resistance

EC50 (pM)

Fold resistance

EC50 (pM)

Fold resistance

EC50 (pM)

Fold resistance

EC50 (pM)

Fold resistance

WT

6.1

1.0

2.2

1.0

4.6

1.0

4.8

1.0

5.5

1.0

Q24K/L28M/R30Q/A92K

2.2 × 105

3.6 × 104

9.6 × 105

4.4 × 105

2.9 × 104

6.3 × 103

1.5 × 104

3.1 × 103

9.8

1.8

Q24K/L28M/R30E/A92K

3.9 × 106

6.4 × 105

1.4 × 106

6.4 × 105

7.1 × 105

1.5 × 105

2.1 × 105

4.4 × 104

8.0 × 103

1.5 × 103

Comparison of R30Q and R30E cell line

17.7-fold

1.5-fold

24.5-fold

14-fold

816.3-fold

  1. The fold change in resistance was compared with that of the WT.
  2. EC50 effective concentration required to inhibit 50%, WT wild-type, NS nonstructural, RAS resistance-associated substitution.
Back to article page